Erik Hansen
Erik Hansen has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Antonia Faustina Chen
Department of Orthopaedics, University of Texas Southwestern, Dallas, Texas
1 shared publication - Carlos A. Higuera
Cleveland Clinic Florida, Weston, United States
1 shared publication - Carol Foltz
The Rothman Institute at Thomas Jefferson University, Philadelphia, Pennsylvania
1 shared publication Carter Powell
1 shared publication- David C. Sing
Division of Spine Surgery, Department of Orthopaedic Surgery, Scripps Clinic, 10710 N Torrey Pines Rd, La Jolla, CA, 92037, United States, 1 8585547988
1 shared publication Frank Voss
1 shared publication
Latest Publications
- Open Access
- 24 December 2025
- Published by Elsevier in Journal of Orthopaedic Reports
- Vol. 5 (4)
Preoperative antibiotic sensitivity testing for total joint replacement
- 24 December 2025
- Published by Elsevier in Journal of Orthopaedic Reports
- Vol. 5 (4)
Open AccessPreoperative antibiotic sensitivity testing for total joint replacement
- 1 January 2020
- Published by Wolters Kluwer Health in JBJS Case Connector
- Vol. 10 (1) , e0250
Technique for Reduction and Fixation of a Hoffa Fracture with Ipsilateral Patella Dislocation from Low-Energy Trauma, a Rare Injury
Case: A 25-year-old man sustained a right femur Hoffa fracture with an ipsilateral patella dislocation from a twisting injury to his right knee. He underwent open reduction and internal fixation of the right femur with medial patellofemoral ligament (MPFL) reconstruction with allograft. One year postoperatively, he had returned to full activity and painless range of motion. Conclusion: Hoffa fracture associated with ipsilateral patella dislocation is a rare injury in young men and warrants judicious clinician awareness. The literature regarding management of this injury combination is minimal, and this report aids in awareness while providing an effective method for treatment.
- 1 January 2020
- Published by Wolters Kluwer Health in JBJS Case Connector
- Vol. 10 (1) , e0250
Technique for Reduction and Fixation of a Hoffa Fracture with Ipsilateral Patella Dislocation from Low-Energy Trauma, a Rare Injury
Case: A 25-year-old man sustained a right femur Hoffa fracture with an ipsilateral patella dislocation from a twisting injury to his right knee. He underwent open reduction and internal fixation of the right femur with medial patellofemoral ligament (MPFL) reconstruction with allograft. One year postoperatively, he had returned to full activity and painless range of motion. Conclusion: Hoffa fracture associated with ipsilateral patella dislocation is a rare injury in young men and warrants judicious clinician awareness. The literature regarding management of this injury combination is minimal, and this report aids in awareness while providing an effective method for treatment.
- 3 April 2019
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 101 (7) , 589-599
Potent Anticoagulation Does Not Reduce Venous Thromboembolism in High-Risk Patients
Background: Based on current guidelines from the American Academy of Orthopaedic Surgeons (AAOS), a number of prophylactic modalities for the prevention of venous thromboembolism in total joint arthroplasty may be used. It is common practice that more potent prophylactic agents are used for patients at higher risk of venous thromboembolism. However, we are aware of no studies that have investigated the efficacy of potent anticoagulation in higher-risk individuals. Therefore, the purpose of our study was to test the hypothesis that low-molecular-weight heparin and warfarin result in a reduction in venous thromboembolism events in high-risk patients. Methods: A retrospective, multi-institutional study of 60,467 primary and revision total joint arthroplasties from 2000 to 2015 was performed. Identified medications were classified as aspirin, low-molecular-weight heparin, or warfarin. Patients with unavailable venous thromboembolism prophylaxis information or those not receiving the aforementioned prophylaxis were excluded. Information pertinent to the objective of this study was collected and a venous thromboembolism risk score was calculated based on 26 variables. Treatment outcomes assessed included 90-day rate of symptomatic venous thromboembolism and periprosthetic joint infection. Propensity score matching was performed (1:1), as well as logistic regression analysis on the total sample. Results: Aspirin prophylaxis demonstrated a lower rate of deep vein thrombosis, pulmonary embolism, and venous thromboembolism than warfarin and low-molecular-weight heparin alone throughout all risk scores. In the matched propensity score analysis, low-molecular-weight heparin and warfarin demonstrated increased odds of venous thromboembolism for both standard-risk and high-risk patients undergoing total knee arthroplasties compared with aspirin. For primary total hip arthroplasty, warfarin demonstrated an increased risk for high-risk patients and low-molecular-weight heparin demonstrated an increased risk for standard-risk patients. The prevalence of periprosthetic joint infection was higher in patients receiving warfarin (p < 0.001 for both comparisons of warfarin with aspirin and low-molecular-weight heparin). Conclusions: The results of this multi-institutional study demonstrate that the use of warfarin and low-molecular-weight heparin in higher-risk patients does not necessarily result in a reduction in symptomatic venous thromboembolism. Aspirin administered to higher-risk patients seems to be as effective as potent anticoagulation and more effective than warfarin. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
- 3 April 2019
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 101 (7) , 589-599
Potent Anticoagulation Does Not Reduce Venous Thromboembolism in High-Risk Patients
Background: Based on current guidelines from the American Academy of Orthopaedic Surgeons (AAOS), a number of prophylactic modalities for the prevention of venous thromboembolism in total joint arthroplasty may be used. It is common practice that more potent prophylactic agents are used for patients at higher risk of venous thromboembolism. However, we are aware of no studies that have investigated the efficacy of potent anticoagulation in higher-risk individuals. Therefore, the purpose of our study was to test the hypothesis that low-molecular-weight heparin and warfarin result in a reduction in venous thromboembolism events in high-risk patients. Methods: A retrospective, multi-institutional study of 60,467 primary and revision total joint arthroplasties from 2000 to 2015 was performed. Identified medications were classified as aspirin, low-molecular-weight heparin, or warfarin. Patients with unavailable venous thromboembolism prophylaxis information or those not receiving the aforementioned prophylaxis were excluded. Information pertinent to the objective of this study was collected and a venous thromboembolism risk score was calculated based on 26 variables. Treatment outcomes assessed included 90-day rate of symptomatic venous thromboembolism and periprosthetic joint infection. Propensity score matching was performed (1:1), as well as logistic regression analysis on the total sample. Results: Aspirin prophylaxis demonstrated a lower rate of deep vein thrombosis, pulmonary embolism, and venous thromboembolism than warfarin and low-molecular-weight heparin alone throughout all risk scores. In the matched propensity score analysis, low-molecular-weight heparin and warfarin demonstrated increased odds of venous thromboembolism for both standard-risk and high-risk patients undergoing total knee arthroplasties compared with aspirin. For primary total hip arthroplasty, warfarin demonstrated an increased risk for high-risk patients and low-molecular-weight heparin demonstrated an increased risk for standard-risk patients. The prevalence of periprosthetic joint infection was higher in patients receiving warfarin (p < 0.001 for both comparisons of warfarin with aspirin and low-molecular-weight heparin). Conclusions: The results of this multi-institutional study demonstrate that the use of warfarin and low-molecular-weight heparin in higher-risk patients does not necessarily result in a reduction in symptomatic venous thromboembolism. Aspirin administered to higher-risk patients seems to be as effective as potent anticoagulation and more effective than warfarin. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.